First Choice

• Rigevidon® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)

Alternatives

• Cilique® (ethinylestradiol 35 microgram/norgestimate 250microgram)
• Femodene® (ethinylestradiol 30 microgram/gestodene 75 microgram)
• Femodene® ED (ethinylestradiol 30 microgram/gestodene 75 microgram)
• Gedarel 30/150® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
• Levest® (ethinylestradiol 35 microgram/norgestimate 250microgram)
• Lizinna® (ethinylestradiol 35 microgram/norgestimate 250 microgram)
• Loestrin 30® (ethinylestradiol 30 microgram/ norethisterone 1.5mg)
• Lucette® (ethinylestradiol 30 microgram/drospirenone 3mg)
• Marvelon® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
• Microgynon® 30 (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
• Microgynon® ED (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
• Millinette 30/75® (ethinylestradiol 30 microgram/ gestodene 75 microgram)
• Ovranette® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)
• Ovysmen® (ethinylestradiol 35 microgram/norethisterone 500 microgram

• Logynon®
• Logynon® ED
• Tri-Regol®

• Evra® are self-adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin/24 hours.
  
  
  
  • Approved for use by a small number of women with gastrointestinal absorption problems or with compliance issues.
  
  
  
  

• Each wallet (28 film-coated tablets) contains in the following order:
  2 dark yellow tablets each containing 3 mg estradiol valerate
  5 medium red tablets each containing 2 mg estradiol valerate and 2 mg dienogest
  17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg dienogest
  2 dark red tablets each containing 1 mg estradiol valerate

• Approved for
  • women who need HRT as well as contraceptive pill, and
  • for heavy menstrual bleeding (HMB)

• 20mcg ethinylestradiol and 3mg drospirenone

• Ethinylestradiol 2.7 mg, Etonogestrel 11.7 mg vaginal ring

• Co-cyprindiol should be reserved for those women requiring treatment for the androgenic conditions such as severe acne or moderately severe hirsutism. It is recommended that treatment be withdrawn 3 to 4 cycles after the androgenic condition(s) has/have completely resolved and that it is not continued solely to provide oral contraception. Venous thromboembolism occurs more frequently in women taking co-cyprindiol than those taking a low-dose combined oral contraceptive. Repeat courses may be given if the androgen-dependent condition(s) recur.
• Note: generic co-cyprindiol is much cheaper than Dianette®